Trial Details
Not RecruitingBasic Information
| Clinical ID | c3173 |
|---|---|
| Identifier | ACTRN12612001107819 |
| Trial Title | Febuxostat-thiopurine combination therapy in patients with moderately severe inflammatory bowel disease (IBD): a pilot study of a novel drug combination that may influence thiopurine bioavailability |
| Trial URL | Visit Original Page |
Study Information
| Study Results | No results available |
|---|---|
| Conditions | inflammatory bowel disease; inflammatory bowel disease;Oral and Gastrointestinal - Inflammatory bowel disease |
| Interventions | To use the combination of febuxostat and 6-mercaptopurine over 4 weeks. 40mg febuxostat will be taken orally once daily together with 6-mercaptopurine at a dose of 1/3 that based on thiopurine methyl transferase activity (TPMT) prediction. (The rule of thumb of 1/3 dosing is based on our published experience with the other xanthine oxidase inhibitor (allopurinol)-thiopurine combination |
Participant Information
| Sponsor | Prof Tim Florin |
|---|---|
| City | - |
| Country/Region | Australia |
Enrollment Criteria
| Sex Requirement | ALL |
|---|---|
| Age Requirement | ADULT, OLDER_ADULT |
Study Design
| Study Type | Interventional |
|---|---|
| Phase | PHASE1 |
Time Information
| Start Date | 2025-04-24 |
|---|---|
| Primary Completion Date | - |
| Completion Date | - |